Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas [Phase 2]
A Phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab as initial therapy for previously untreated follicular…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas [Phase 2]
This Phase 2 clinical trial update describes evaluating rituximab in combination with zanubrutinib for indolent B-cell lymphomas, including …
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma [Phase 1]
An early-phase study evaluating the combination of parsaclisib with standard therapy in newly diagnosed, high-risk diffuse large B-cell lymp…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A clinical trial update describes EO2463, a novel vaccine, being studied as monotherapy and in combination for indolent non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment [Phase 2]
This update summarizes a Phase 2 trial of zanubrutinib (BGB-3111) in participants with previously treated B-cell lymphomas intolerant to pri…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. [Phase 2]
Phase 2 trial investigating orelabrutinib as consolidation and maintenance therapy in treatment-naïve marginal zone lymphoma, currently recr…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocy…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractor…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role
An ongoing clinical trial is evaluating FDG PET imaging as a prognostic tool in marginal zone lymphoma. The study is sponsored by the Intern…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma [Phase 4]
Phase 4 trial evaluating Orelabrutinib with or without a CD20 monoclonal antibody in previously untreated marginal zone lymphoma is currentl…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]
A Phase 2 study is evaluating the combination of mosunetuzumab and zanubrutinib in relapsed/refractory marginal zone lymphoma. The trial is …
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating response-adapted ultra-low-dose 4 Gy radiation as definitive therapy for Marginal Zone Lymphoma is current…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial is evaluating mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular lymphoma and marginal zone l…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 trial is evaluating the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed indolent …
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 clinical trial of Axicabtagene Ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (follicular and marginal zone lymphom…
-
CLINICAL_TRIALS other · 2025-12-23Clinical Trial Update: Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma [NA]
Clinical trial update describing a first-line treatment using zanubrutinib, rituximab, and lenalidomide for Marginal Zone Lymphoma.
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma [Phase 3]
Phase 3 randomized trial comparing Mosunetuzumab-Lenalidomide to the investigator's choice in relapsed or refractory marginal zone lymphoma;…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma [Phase 1]
An ongoing Phase 1 clinical trial update for AS-1763 in adults with previously treated B-cell malignancies, including chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) [Phase 2]
This Phase 2 trial is evaluating pirtobrutinib in combination with rituximab for untreated marginal zone lymphoma and is currently recruitin…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 clinical trial update on Pemigatinib in relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell lymphoma and marg…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of pevonedistat in combination with ibrutinib for relapsed or refractory chronic lympho…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Watch and Wait or Worry and Wait in Indolent Lymphoma
An ongoing clinical trial at Seoul National University Hospital is evaluating watchful waiting versus proactive worry-and-wait strategies in…